Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Change in Accured Expenses (2023 - 2025)

Kura Oncology (KURA) has disclosed Change in Accured Expenses for 3 consecutive years, with -$2.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 115.07% to -$2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.7 million, a 24.8% decrease, with the full-year FY2025 number at $12.7 million, down 24.8% from a year prior.
  • Change in Accured Expenses was -$2.2 million for Q4 2025 at Kura Oncology, down from $12.7 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $14.3 million in Q4 2024 to a low of -$5.4 million in Q1 2025.
  • A 3-year average of $3.4 million and a median of $4.0 million in 2023 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 15150.0% in 2025; the steepest drop was 115.07% in 2025.
  • Kura Oncology's Change in Accured Expenses stood at $8.6 million in 2023, then skyrocketed by 67.2% to $14.3 million in 2024, then plummeted by 115.07% to -$2.2 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Change in Accured Expenses are -$2.2 million (Q4 2025), $12.7 million (Q3 2025), and $7.5 million (Q2 2025).